NCT04557384
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic antibody, Endocrine (Hormone) therapy, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients who have received IV ramucirumab in the past; Patients with uncontrolled unstable symptomatic brain metastasis- see trial for details (screening not required)
https://ClinicalTrials.gov/show/NCT04557384